Jurjen Versluis: Allogeneic HCT should be considered as a curative treatment for all patients with high-risk MDS.
Jurjen Versluis, Internist hematologist and Researcher at Erasmus MC, shared the following insights on Twitter:
“Excited to share our paper in the Journal of Clinical Oncology: allogeneic HCT should be considered as a curative treatment for all patients with high-risk MDS, even for those with TP53 mutations.
Thanks to all collaborators: Coleman Lindsley, Corey Cutler, Chris Hourigan, Blood and Marrow Transplant Clinical Trials Network.”
He continued on with:
“Struggling with the character limit in my first “Xeet”. Thanking Ryo Nakamura, Wael Saber, Chris Gibson, Laura Dillon, Mary Horowitz, Brent Logan, Michael Martens, and all other collaborators not on X. Dana-Farber Cancer Institute, Erasmus MC, Erasmus MC Hematology.”
For details click here.
Source: Jurjen Versluis / Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023